Why low-cost ketamine is still inaccessible to many with severe depression | The George Institute for Global Health
www.georgeinstitute.org.au
A case study on ketamine reveals systemic barriers that prevent repurposing existing low-cost drugs like ketamine for treatment-resistant depression.
This is an automated archive made by the Lemmit Bot.

The original was posted on /r/australia by /u/drdrugsandbrains on 2023-10-24 03:27:33.

Original Title: Australians with depression struggle to access potentially life-changing treatment with ketamine because current systems prioritize profits over patients. New paper reveals the systemic barriers preventing the repurposing of low-cost drugs.